| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
WAY-303290 targets GluR6 (also known as GRIK2), an ionotropic glutamate receptor belonging to the kainate receptor family. GluR6 is a ligand-gated ion channel that mediates fast excitatory neurotransmission in the central nervous system and is involved in synaptic plasticity, learning, and memory. By acting as a GluR6 antagonist, WAY-303290 blocks glutamate-induced ion flux through the receptor, thereby modulating glutamatergic signaling.
|
|---|---|
| ln Vitro |
In vitro, WAY-303290 is a benzothiophene derivative that acts as an ionotropic glutamate receptor 6 (GluR6) antagonist. It inhibits the pY binding site of the tyrosine kinase p56lck SH2 domain. The compound's antagonism of GluR6 makes it valuable for studying the role of kainate receptors in neurological disorders. However, specific IC50 values and detailed in vitro activity data have not been reported in the available literature.
|
| ln Vivo |
In vivo, WAY-303290 has potential applications in researching acute and chronic neurological disorders. By antagonizing GluR6, the compound may modulate glutamatergic signaling and have therapeutic potential for conditions involving glutamate excitotoxicity. However, specific in vivo efficacy data for WAY-303290 have not been detailed in the available literature. Further preclinical studies would be required.
|
| Enzyme Assay |
For in vitro receptor binding and functional assays, cells expressing GluR6 receptors are incubated with radiolabeled ligands or agonists at various concentrations of WAY-303290 (0.1-100 µM). Receptor binding affinity is measured using radioligand binding assays. Functional antagonism is assessed by measuring calcium flux or electrophysiological recordings in response to glutamate stimulation in the presence of the compound.
|
| Cell Assay |
For cell-based assays, neurons or cell lines expressing GluR6 are treated with WAY-303290 at concentrations ranging from 0.1-100 µM. Receptor activation is assessed by measuring calcium influx using calcium-sensitive fluorescent dyes or by electrophysiological recordings. Cell viability and neurotoxicity can also be assessed in models of glutamate excitotoxicity.
|
| Animal Protocol |
For in vivo studies, animal models of neurological disorders such as epilepsy, stroke, or neurodegenerative diseases would be used. WAY-303290 would be administered via appropriate routes at doses determined from pharmacokinetic studies. Neurological outcomes, seizure activity, or neuroprotection would be assessed. However, specific in vivo protocols for WAY-303290 have not been detailed in the available literature.
|
| ADME/Pharmacokinetics |
WAY-303290 is soluble in DMSO. Storage is recommended at -20°C for 3 years (powder) or -20°C for 1 month or -80°C for 6 months in solvent. Further detailed PK parameters including half-life, oral bioavailability, and tissue distribution would be required for in vivo studies. The compound is for research use only and is not intended for human or veterinary use.
|
| Toxicity/Toxicokinetics |
Toxicological data for WAY-303290 have not been extensively reported. As a research compound, it is intended for laboratory use only and is not for human or veterinary use. Standard safety precautions should be followed when handling this compound. Comprehensive toxicology studies would be required before any clinical development.
|
| References | |
| Additional Infomation |
WAY-303290 (GluR6 antagonist-1) is a benzothiophene derivative acting as an ionotropic glutamate receptor 6 (GluR6) antagonist. It can be used for researching acute and chronic neurological disorders. WAY-303290 is a research tool for studying glutamatergic signaling and neurological diseases. It is not approved for clinical use.
|
| Molecular Formula |
C15H11CLN2OS
|
|---|---|
| Molecular Weight |
302.78
|
| Exact Mass |
302.028
|
| CAS # |
323176-64-3
|
| PubChem CID |
673385
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
543.5±50.0 °C at 760 mmHg
|
| Flash Point |
282.5±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.688
|
| LogP |
3.71
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=C(S2)C(=O)NCC3=CN=CC=C3)Cl
|
| InChi Key |
FLKPRONUHHJNKH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H11ClN2OS/c16-13-11-5-1-2-6-12(11)20-14(13)15(19)18-9-10-4-3-7-17-8-10/h1-8H,9H2,(H,18,19)
|
| Chemical Name |
3-chloro-N-(pyridin-3-ylmethyl)-1-benzothiophene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3027 mL | 16.5136 mL | 33.0273 mL | |
| 5 mM | 0.6605 mL | 3.3027 mL | 6.6055 mL | |
| 10 mM | 0.3303 mL | 1.6514 mL | 3.3027 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
